FeedworthyAI
Back to feed
GEN – Genetic Engineering and Biotechnology Newsnews

Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm

Friday, September 11, 2026John SterlingView original

Alongside decisions involving capacity expansion, officials at Samsung Biologics announced that the company is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities.

The post Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm appeared first on GEN - Genetic Engineering and Biotechnology News.